← All trials
NCT06267872
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 7, 2024
- Primary completion
- Dec 30, 2025
- Completion date
- Sep 12, 2026
- First posted
- Feb 20, 2024
- Last posted
- Sep 27, 2024
- Enrollment
- 42
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Department of Health and Human ServicesCollaborator
- Access to Advanced Health Institute (AAHI)Collaborator
- Duke UniversityCollaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.